Cocrystal Pharma (COCP) Liabilities and Shareholders Equity (2010 - 2026)

Cocrystal Pharma has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $7.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 30.33% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.1 million (down 41.72% YoY) and the FY2025 annual result came in at $9.7 million, down 27.82% from the prior year.
• Liabilities and Shareholders Equity retreated to $7.4 million in Q1 2026 per COCP's latest filing, from $9.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $75.4 million in Q1 2022 and troughed at $7.4 million in Q1 2026.
• A 5-year average of $28.0 million and a median of $26.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 39.96% in 2022, then tumbled 60.58% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $40.8 million in 2022, then slipped by 23.46% to $31.3 million in 2023, then plunged by 56.95% to $13.5 million in 2024, then decreased by 27.82% to $9.7 million in 2025, then dropped by 23.54% to $7.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.4 million, $9.7 million, and $10.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.